Clementia Pharmaceuticals Inc (CMTA): B.Riley FBR Keeps “Buy” Rating Today, Has a Target of $25.0000/Share

May 25, 2018 - By Vivian Currie

Clementia Pharmaceuticals Inc (CMTA) Rating Reaffirmed

In a report revealed to investors and clients on Wednesday morning, The “Buy” rating of Clementia Pharmaceuticals Inc (CMTA) shares was restate by B.Riley FBR, who now has a $25.0000 target price per share on the stock. B.Riley FBR’s target price per share would suggest a possible upside of 66.22 % from the last price of the company.

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) Ratings Coverage

Among 2 analysts covering Clementia Pharmaceuticals Inc (CMTA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clementia Pharmaceuticals Inc has $2500 highest and $25 lowest target. $25’s average target is 66.22% above currents $15.04 stock price. Clementia Pharmaceuticals Inc had 2 analyst reports since March 27, 2018 according to SRatingsIntel. The rating was initiated by FBR Capital with “Buy” on Tuesday, March 27.

The stock increased 1.28% or $0.19 during the last trading session, reaching $15.04. About 161,303 shares traded or 229.63% up from the average. Clementia Pharmaceuticals Inc. (CMTA) has 0.00% since May 25, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) to report earnings on August, 9. After $-0.42 actual EPS reported by Clementia Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -14.29 % EPS growth.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $477.03 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

More notable recent Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) news were published by: Benzinga.com which released: “33 Stocks Moving In Wednesday’s Mid-Day Session” on May 23, 2018, also Streetinsider.com with their article: “Clementia Pharmaceuticals (CMTA) Highlights Positive Phase 2 Part B Data from Ongoing Phase 2 Clinical Trial …” published on May 23, 2018, Globenewswire.com published: “Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates” on May 09, 2018. More interesting news about Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) were released by: Schaeffersresearch.com and their article: “Tiffany Stock Eyes Best Day in Years After Earnings, Share Buyback” published on May 23, 2018 as well as Businesswire.com‘s news article titled: “Prevail Therapeutics Appoints Industry Leader Francois Nader, MD, to its Board of Directors” with publication date: May 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.